CoChat

Antidepressants from a public health perspective: re‐examining effectiveness, suicide, and carcinogenicity

Nassir Ghaemi, S., Vohringer, P. A., Whitham, E. A. · 2013 · Acta Psychiatrica Scandinavica
Cited by 15

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Abstract

The widespread use of antidepressants has rarely been critiqued from a public health perspective. It is as although the medical profession has felt that depression in the community at large could be resolved by the widespread diagnosis of major depressive disorder (MDD) in people with depressive symptoms and subsequent prescription of antidepressant medication. This broad approach to diagnosis and treatment grows out of the medical approach to illness. In this editorial, we examine the need for a public health approach to the prevention and treatment of depression, as well as a better understanding of the valid role of antidepressants in such treatment. In clinical psychiatry, the diagnosis of depression is usually given to people who have severe recurrent episodes of depression, conceived as a syndrome of multiple physical as well as psychological symptoms 1. Traditionally, from the late 19th century until 1980, when the psychiatric nosology was revised to the current approach first defined in DSM-III, depression as a disease was identified in three categories: manic depressive illness (MDI), melancholia, and neurotic depression. MDI meant recurrent severe depressive or manic episodes. Melancholia meant severe depressive mood with marked psychomotor retardation, anhedonia, and a complete lack of change in mood even with positive environmental circumstances. Neurotic depression involved mild-to-moderate chronic anxiety with depression, without a highly recurrent course (as in manic depression), without marked psychomotor retardation (as in melancholia). The melancholic subtype of depression is currently included in DSM-IV and ICD-10, but the concept of depression has been widened to include all kinds of depressive symptoms including: chronic mild to moderate depression, anxiety, agitated depression, and highly reactive and labile mood presentations. In the old MDI concept, the presence of depression vs. mania was irrelevant to diagnosis 1. What was relevant was the course of illness consisting of any repeated severe mood episodes alternating with periods of normal mood or markedly decreased mood symptoms. The current major depressive disorder (MDD) definition ignores this course: the presence of depression is all that is needed, and the course of illness can be recurrent, as in the original MDI concept with periods of normal mood, or highly chronic, as is perhaps the case with the majority of patients currently receiving the MDD diagnosis. Furthermore, the MDD concept implies that depression is a homogeneous entity, whereas for a century, this has been an unresolved matter: Is depression one thing or many 2, 3? It is possible that the disparate nature of this MDD category has led to a state where a potential biological disease characterized by depression, such as MDI, is mixed with many other depressive symptom presentations which are not owing to a biological disease of depression, such as solely psychosocially caused depressive symptoms. The possibility that such a broad mixture of different depressive causes may be incorporated into the MDD category is suggested by the increasing evidence that antidepressant medications, which may be effective for the biological disease of depression, appear to be decreasingly effective in our current MDD definitions 4-6, with markedly heterogeneous results in a long-term basis 7, 8. As has been widely discussed in the lay media, some reanalyses of the FDA database of antidepressants trials indicate that these medications are not much more effective than placebo 4. Although presented in a way to suggest almost no benefit at all, a more statistically accurate interpretation of those data indicate that antidepressants are more clearly effective in moderate-to-severe acute depressive episodes, as opposed to mild episodes 9. Moreover, some explanation for the apparently modest clinical effect of antidepressants could be found in how depressive episodes are measured and how unreliable symptoms scales could be, reflecting in turn the heterogeneity of the underlying construct 10. The evidence from the large FDA database is limited to short-term effects for acute depressive episodes, usually meaning about 2 months in duration. Most patients take antidepressants for years, and, given a limited randomized literature on that topic 11, the best evidence probably comes from the largest relevant study: the NIMH-sponsored study of MDD treatment with antidepressants called STAR*D (Sequenced Treatment Alternatives for Resistant Depression) 12. In this study, over 3000 patients were initially treated with the serotonin reuptake inhibitor (SRI) citalopram. The patients that did not respond were then treated with other antidepressants either alone or in combination with the first antidepressant. Those patients who failed to respond to the second level of treatment were treated with older antidepressants, such as tricyclic antidepressants, and the final level of treatment (the non-responders

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/acps.12059

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 15

Metadata

Authors
Nassir Ghaemi, S., Vohringer, P. A., & Whitham, E. A.
Venue
Acta Psychiatrica Scandinavica
Publisher
Wiley
Published
2013-01-09
Volume
127
Issue
2
Pages
89-93
ISSN
  • 0001-690X (ISSN-L)
  • 1600-0447
OpenAlex
W1976552049
Cited by
15
References
9
FWCI
2.61
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.